vs
HOPE BANCORP INC（HOPE）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是HOPE BANCORP INC的1.5倍（$207.3M vs $141.0M），HOPE BANCORP INC净利率更高（20.9% vs -62.0%，领先83.0%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 21.0%），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 9.8%）
希望银行（Bank of Hope）是总部位于美国洛杉矶的银行机构，前身为1980年12月30日成立的威尔希尔银行，核心服务群体为韩裔美国人社区，在当地族裔金融服务领域拥有长期的运营经验。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
HOPE vs RARE — 直观对比
营收规模更大
RARE
是对方的1.5倍
$141.0M
营收增速更快
RARE
高出4.8%
21.0%
净利率更高
HOPE
高出83.0%
-62.0%
两年增速更快
RARE
近两年复合增速
9.8%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $141.0M | $207.3M |
| 净利润 | $29.5M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | — | -54.7% |
| 净利率 | 20.9% | -62.0% |
| 营收同比 | 21.0% | 25.9% |
| 净利润同比 | — | 3.5% |
| 每股收益（稀释后） | $0.23 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HOPERARE
| Q1 26 | $141.0M | — | ||
| Q4 25 | $145.8M | $207.3M | ||
| Q3 25 | $141.9M | $159.9M | ||
| Q2 25 | $94.5M | $166.5M | ||
| Q1 25 | $116.5M | $139.3M | ||
| Q4 24 | $118.0M | $164.6M | ||
| Q3 24 | $116.6M | $139.5M | ||
| Q2 24 | $116.9M | $147.0M |
净利润HOPERARE
| Q1 26 | $29.5M | — | ||
| Q4 25 | — | $-128.6M | ||
| Q3 25 | $30.8M | $-180.4M | ||
| Q2 25 | $-24.8M | $-115.0M | ||
| Q1 25 | $21.1M | $-151.1M | ||
| Q4 24 | — | $-133.2M | ||
| Q3 24 | $24.2M | $-133.5M | ||
| Q2 24 | $25.3M | $-131.6M |
营业利润率HOPERARE
| Q1 26 | — | — | ||
| Q4 25 | 26.8% | -54.7% | ||
| Q3 25 | 25.6% | -106.9% | ||
| Q2 25 | -27.6% | -64.8% | ||
| Q1 25 | 23.9% | -102.6% | ||
| Q4 24 | 25.8% | -74.3% | ||
| Q3 24 | 27.5% | -94.6% | ||
| Q2 24 | 29.5% | -79.1% |
净利率HOPERARE
| Q1 26 | 20.9% | — | ||
| Q4 25 | — | -62.0% | ||
| Q3 25 | 21.7% | -112.8% | ||
| Q2 25 | -26.2% | -69.0% | ||
| Q1 25 | 18.1% | -108.5% | ||
| Q4 24 | — | -80.9% | ||
| Q3 24 | 20.7% | -95.7% | ||
| Q2 24 | 21.6% | -89.5% |
每股收益（稀释后）HOPERARE
| Q1 26 | $0.23 | — | ||
| Q4 25 | $0.27 | $-1.28 | ||
| Q3 25 | $0.24 | $-1.81 | ||
| Q2 25 | $-0.19 | $-1.17 | ||
| Q1 25 | $0.17 | $-1.57 | ||
| Q4 24 | $0.20 | $-1.34 | ||
| Q3 24 | $0.20 | $-1.40 | ||
| Q2 24 | $0.21 | $-1.52 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.3B | $-80.0M |
| 总资产 | $18.7B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资HOPERARE
| Q1 26 | — | — | ||
| Q4 25 | — | $421.0M | ||
| Q3 25 | — | $202.5M | ||
| Q2 25 | — | $176.3M | ||
| Q1 25 | — | $127.1M | ||
| Q4 24 | — | $174.0M | ||
| Q3 24 | — | $150.6M | ||
| Q2 24 | — | $480.7M |
股东权益HOPERARE
| Q1 26 | $2.3B | — | ||
| Q4 25 | $2.3B | $-80.0M | ||
| Q3 25 | $2.3B | $9.2M | ||
| Q2 25 | $2.2B | $151.3M | ||
| Q1 25 | $2.2B | $144.2M | ||
| Q4 24 | $2.1B | $255.0M | ||
| Q3 24 | $2.2B | $346.8M | ||
| Q2 24 | $2.1B | $432.4M |
总资产HOPERARE
| Q1 26 | $18.7B | — | ||
| Q4 25 | $18.5B | $1.5B | ||
| Q3 25 | $18.5B | $1.2B | ||
| Q2 25 | $18.5B | $1.3B | ||
| Q1 25 | $17.1B | $1.3B | ||
| Q4 24 | $17.1B | $1.5B | ||
| Q3 24 | $17.4B | $1.5B | ||
| Q2 24 | $17.4B | $1.6B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | — | $-100.8M |
| 自由现金流率自由现金流/营收 | — | -48.6% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-472.0M |
8季度趋势，按日历期对齐
经营现金流HOPERARE
| Q1 26 | — | — | ||
| Q4 25 | $164.5M | $-99.8M | ||
| Q3 25 | $51.7M | $-91.4M | ||
| Q2 25 | $9.4M | $-108.3M | ||
| Q1 25 | $26.7M | $-166.5M | ||
| Q4 24 | $116.7M | $-79.3M | ||
| Q3 24 | $63.0M | $-67.0M | ||
| Q2 24 | $-25.6M | $-77.0M |
自由现金流HOPERARE
| Q1 26 | — | — | ||
| Q4 25 | $151.5M | $-100.8M | ||
| Q3 25 | $47.2M | $-92.7M | ||
| Q2 25 | $6.9M | $-110.7M | ||
| Q1 25 | $24.0M | $-167.8M | ||
| Q4 24 | $106.9M | $-79.5M | ||
| Q3 24 | $60.1M | $-68.6M | ||
| Q2 24 | $-28.1M | $-79.0M |
自由现金流率HOPERARE
| Q1 26 | — | — | ||
| Q4 25 | 103.9% | -48.6% | ||
| Q3 25 | 33.2% | -58.0% | ||
| Q2 25 | 7.3% | -66.5% | ||
| Q1 25 | 20.6% | -120.5% | ||
| Q4 24 | 90.6% | -48.3% | ||
| Q3 24 | 51.6% | -49.2% | ||
| Q2 24 | -24.0% | -53.7% |
资本支出强度HOPERARE
| Q1 26 | — | — | ||
| Q4 25 | 9.0% | 0.5% | ||
| Q3 25 | 3.2% | 0.8% | ||
| Q2 25 | 2.6% | 1.5% | ||
| Q1 25 | 2.3% | 1.0% | ||
| Q4 24 | 8.3% | 0.1% | ||
| Q3 24 | 2.5% | 1.2% | ||
| Q2 24 | 2.2% | 1.4% |
现金转化率HOPERARE
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 1.68× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 1.26× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.61× | — | ||
| Q2 24 | -1.01× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HOPE
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
